PTJA04 – “Sotagliflozin indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy” is now available
This is the assessment of the relative effectiveness of ‘Sotagliflozin indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy.’ Below is the documentation provided by […]
Open Call for Patient Group Input – Collaborative Assessment on a Medical Device for Rectum Spacers for Prostate Cancer Radiotherapy
EUnetHTA recently started a new Collaborative Assessment on a Medical Device for rectum spacers for prostate cancer radiotherapy. To find out about participation, please read more here. Input submissions will be received through EOB, Friday 5th July.
Open Call for Patient Input – Joint Assessment on a medicinal product for neovascular (wet) age-related macular degeneration (AMD).
EUnetHTA recently started a new Joint Assessment on a medicinal product for neovascular (wet) age-related macular degeneration (AMD). To find out about participation, please read more here. Input submissions will be received through 13:00, July 15th.
REQueST tool and its Vision paper Public Consultation – Now closed
The Haute Autorité de Santé (HAS), National Institute for Health and Care Excellence (NICE) & the Croatian Institute for Public Health (HZJZ) are pleased to share the following WP5 strand B draft outputs for an 8 week public consultation: REQueST (Registry Evaluation and Quality Standards Tool): a tool that is built upon the results of […]
EUnetHTA 2019 Assembly & Forum Welcome Guide – Now Available
To accompany the upcoming EUnetHTA 2019 Assembly & Forum 0n 10-11th April in Amsterdam, a Welcome Guide has been developed to give participants and attendees a thorough overview of the event proceedings, practical information, and EUnetHTA’s working activities. The guide is created through the direct input of all EUnetHTA working groups and aims to […]
Open Call for Patient Input – Joint Assessment on a medicinal product for secondary progressive MS.
EUnetHTA recently started a new Joint Assessment on a medicinal product for secondary progressive MS. To find out about participation, please read more here. Input submissions will be received through till EOB, April 28th.
2019 EUnetHTA Forum Agenda – Now Available
The day’s agenda is now available for the upcoming 2019 EUnetHTA Forum on 11th April at the West-Indisch Huis in central Amsterdam. We are looking forward to hosting a collaborative, informative session of talks that both outline progress made in European HTA, while scoping out expectations for the future. See the agenda HERE.
EUnetHTA Magazine: Winter 2019
Assessment Publication: Jointly Produced HTA Report; Partner Profile: Austria; Impact: Austria; Partner Profile: UK; Innovation & HTA: Giovanni Tafuri; Prioritisation List: Topics & Joint Assessments; 2018: Year in Review Download your copy HERE.
Open Call for Patient Input – Joint Assessment on a Medicinal Product for UC.
EUnetHTA recently started a new Joint Assessment on a medicinal product for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response with. lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contraindications to such therapies. To find out […]
Open Call for Patient Input – Joint Assessment on a Medicinal Product for DBLCL.
EUnetHTA recently started a new Joint Assessment on a medicinal product for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for hematopoietic stem cell transplant. To find out more about how patient input can contribute to this assessment, please read further here. Input is greatly appreciated […]
